||Robert A. Essner
Former Chairman & CEO Wyeth
Executive-in-Residence Columbia Business School
||Edward J. Ludwig ('75)
Chairman & CEO
BD (Becton Dickinson)
Director, Healthcare and Pharmaceutical Management Program
Adjunct Professor, Columbia Business School
25 years as a senior professional in the financial services and
healthcare/ pharmaceutical sectors. He was Managing Director
Merrill Lynch and JP Morgan in their global healthcare investment
banking groups, and Vice President, Corporate Planning &
Development at Merck & Co., Inc., with worldwide
for strategic planning and business development.
previous experiences also include the co-founding of American Health
Capital / VHA Enterprises, Inc., a healthcare/ financial services firm
serving the capital needs of multi-hospital systems and other
healthcare providers, and investment banking positions with Paine
Webber, Inc. and L.F. Rothschild, Unterberg, Towbin, Inc.
Director of the Healthcare and Pharmaceutical Management Program and
Adjunct Professor at Columbia University, Graduate School of Business.
He teaches two courses in
the spring semester: Strategy and Competition in
Pharmaceuticals and Biotechnology, and Healthcare
Investment and Dealmaking.
Linda V. Green, PhD
Armand G. Erpf Professor, Columbia Business School
Green is the
Armand G. Erpf Professor at Columbia Business School. She earned her
doctorate in Operations Research from Yale University. Her research,
which has focused on the development and application of mathematical
models of service systems, has resulted in dozens of publications in
the major technical journals including Operations Research,
Management Science, and The Journal of Applied
Probability as well as prominent healthcare journals such as Health
Services Research, Inquiry and Academic Emergency
early work led to the development of a model for the dispatching and
allocation of emergency vehicles which became the foundation for a
patrol car allocation model that is used by many major cities in the
U.S. as well as several other countries. Her current research is on
identifying operational policies to improve the delivery of healthcare.
Specific projects focus on improving emergency responsiveness,
developing strategies for the efficient and effective use of major
diagnostic equipment such as MRIs, providing timely access to primary
care, and the development of a new nurse staffing methodology. She is a
co-founder and co-director of the Columbia Alliance for Healthcare
Management, a unique partnership of the College of Physicians and
Surgeons, the Mailman School of Public Health and the Business School
of Columbia University dedicated to promoting interdisciplinary
research and education in healthcare management. She has been a
consultant for both private and public sector organizations and has
served on several advisory boards. She has served in many
administrative positions at both Columbia and in the major professional
societies and is currently the Department Editor for Public Sector
Applications for the journal Management
In recognition of her professional achievements, Professor Green was
elected a Fellow of INFORMS, the premier international professional
society for operations research and management science.
Moderator: Frank R.
Courtney C. Brown Professor of Business
Columbia Universtiy Graduate School of Business
Lichtenberg is Courtney C. Brown Professor of Business at the Columbia
University Graduate School of Business, and a Research Associate of the
National Bureau of Economic Research. He received a BA with
Honors in History from the University of Chicago and an MA and PhD in
Economics from the University of Pennsylvania.
Professor Lichtenberg previously taught at Harvard University and the
University of Pennsylvania. He has served as an expert for
the Federal Trade Commission, the U.S. Dept. of Justice, and state
Attorneys General, and has testified before Congress. He has
worked for several U.S. government agencies, including the Department
of Justice, the Congressional Budget Office, and the Census Bureau, and
been a visiting scholar at the Wissenschaftszentrum Berlin, the
University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the
introduction of new technology arising from research and development
affects the productivity of companies, industries and nations. Recently
he has performed studies of the impact of pharmaceutical innovation on
longevity, the effect of computers on productivity in business and
government organizations, and the consequences of takeovers and
leveraged buyouts for efficiency and employment. His articles
have been published in numerous scholarly journals and in the popular
press. His book Corporate Takeovers and Productivity has been
published by MIT Press. He was awarded the 1998 Schumpeter
Prize for his paper, Pharmaceutical Innovation as a Process of Creative
Destruction, and a 2003 Milken Institute Award for Distinguished
Economic Research for the paper, Pharmaceutical Knowledge-Capital
Accumulation and Longevity.
He has been awarded research fellowships, grants, and contracts by the
National Science Foundation, the National Institute of Standards and
Technology, Merck and Co., the Fulbright Commission, the Brookings
Institution, the Alfred P. Sloan Foundation, The German Marshall Fund,
the American Enterprise Institute, and other organizations.
He has served as a consultant to private organizations and government
agencies including the Securities Industry Association, Pfizer, Inc.,
the Community Preservation Corporation, the RAND Corporation, the New
York City Water Board, Touche Ross and Co., The Walt Disney Company,
McGraw-Hill, and the National Pharmaceutical Council. He is an
Affiliate of the economics consulting firm LECG, LLC.
Assistant Director, Healthcare and Pharmaceutical Management Program,
Columbia Business School
graduating from Columbia Business School
in 1984, Gary held a number of positions in the
industry. As a marketing research analyst at Merck, Gary
was involved in a variety of internal consulting projects in the areas
of pricing, cost-benefit analysis, marketing, and strategic planning.
As a product manager at Abbott Laboratories, Gary was deeply
involved in formulating promotional and anti-generics strategies for
the company's largest revenue drug product at the time. As a
strategic planner at Pfizer, Gary coordinated inter-disciplinary teams
responsible for the completion of the pharmaceutical
division’s five-year strategic
On Wall Street,
Gary was a managed healthcare analyst during the
nineties. At Deutsche Bank and Bear Stearns, Gary formulated
single-stock and industrywide stock allocation
recommendations in the healthcare services sectors. He
quoted in The Wall Street Journal and on CNN and CNBC on managed care
healthcare reform issues.
After his career
on Wall Street Gary led Oxford Health Plans’
Investor Relations and Public Relations departments as Senior
Vice President of Corporate Communications and founded his own investor
relations consulting firm--Frazier Consulting, LLC.
of the HCIA are first- and second-year MBA students pursuing careers in
the healthcare industry.